Search results for "Replacement therapy"

showing 10 items of 289 documents

Ophthalmological Findings in Mucopolysaccharidoses

2019

The mucopolysaccharidoses (MPS) are a heterogenous group of lysosomal storage disorders caused by the accumulation of glycosaminoglycans (GAGs). The accrual of these compounds results in phenotypically varied syndromes that produce multi-organ impairment with widespread systemic effects. The low incidence of MPS (approximately 1/25,000 live births) in conjunction with the high childhood mortality rate had limited the availability of research into certain clinical features, especially ocular manifestations. As the recent successes of hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) have greatly increased life expectancy in these patients, they have served a…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMucopolysaccharidosislcsh:MedicineGlaucomaReviewHematopoietic stem cell transplantation03 medical and health sciences0302 clinical medicineQuality of lifeCorneal cloudingmedicinebusiness.industryMortality rateIncidence (epidemiology)lcsh:Rnutritional and metabolic diseasesmucopolysaccharidosisGeneral MedicineEnzyme replacement therapymedicine.diseaseocular manifestationseye diseasesophthalmology030104 developmental biologycorneal clouding030221 ophthalmology & optometrylysosomal storage disordersense organsbusinessJournal of Clinical Medicine
researchProduct

CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.

2020

During the past decades, several therapeutic approaches have been developed and made rapidly available for many patients afflicted with lysosomal storage disorders (LSDs), inborn organelle disorders with broad clinical manifestations secondary to the progressive accumulation of undegraded macromolecules within lysosomes. These conditions are individually rare, but, collectively, their incidence ranges from 1 in 2,315 to 7,700 live-births. Most LSDs are manifested by neurological symptoms or signs, including developmental delay, seizures, acroparesthesia, motor weakness, and extrapyramidal signs. The chronic and later-onset clinical forms are at one end of the continuum spectrum and are char…

0301 basic medicineliposomesWeaknessLysosomal storage disordersReviewexosomesBioinformaticsBiochemistry Genetics and Molecular Biology (miscellaneous)BiochemistryExtracellular vesiclesUnmet needs03 medical and health sciences0302 clinical medicinelysosomesSlow progressionmedicineMolecular Bioscienceslcsh:QH301-705.5Molecular BiologytherapyExtrapyramidal signsbusiness.industryEnzyme replacement therapygene therapysmall molecules030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesismedicine.symptombusinessextracellular vesiclesNeurological problemsenzyme replacement therapyFrontiers in molecular biosciences
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome

2018

Abstract Aim Mucopolysaccharidosis type I is a lysosomal storage disorder that can result in significant disease burden, disability and premature death, if left untreated. The aim of this review was to elaborate on the diagnosis of mucopolysaccharidosis type I and the pros and cons of newborn screening. Methods An international working group was established to discuss ways to improve the early diagnosis of mucopolysaccharidosis type I. It consisted of 13 experts in paediatrics, rare diseases and inherited metabolic diseases from Europe and the Middle East. Results It is becoming increasingly clearer that the delay between symptom onset and clinical diagnosis is considerable for mucopolysacc…

0301 basic medicinemedicine.medical_specialtyHaematopoietic stem cell transplantLysosomal storage disorderMucopolysaccharidosis ILysosomal storage disordersReview ArticleDisease03 medical and health sciencesMucopolysaccharidosis type INeonatal Screening0302 clinical medicinemedicineHumansLaronidasePediatrics Perinatology and Child HealthIntensive care medicineReview ArticlesDisease burdenNewborn screeningbusiness.industryMucopolysaccharidosis type IInfant NewbornGeneral MedicineEnzyme replacement therapyInternational working group030104 developmental biologyEnzyme replacement therapyClinical diagnosisPediatrics Perinatology and Child Healthbusiness030217 neurology & neurosurgeryActa Paediatrica
researchProduct

Leukocyte and Skeletal Muscle Telomere Length and Body Composition in Monozygotic Twin Pairs Discordant for Long-term Hormone Replacement Therapy

2017

Estrogen-based hormone replacement therapy (HRT) may be associated with deceleration of cellular aging. We investigated whether long-term HRT has effects on leukocyte (LTL) or mean and minimum skeletal muscle telomere length (SMTL) in a design that controls for genotype and childhood environment. Associations between telomeres, body composition, and physical performance were also examined. Eleven monozygotic twin pairs (age 57.6 ± 1.8 years) discordant for HRT were studied. Mean duration of HRT use was 7.3 ± 3.7 years in the user sister, while their co-twins had never used HRT. LTL was measured by qPCR and SMTLs by southern blot. Body and muscle composition were estimated by bioimpedance an…

0301 basic medicinemedicine.medical_specialtymedicine.drug_classMonozygotic twinmedicine.disease_cause03 medical and health sciencesGrip strengthJumpingInsulin resistanceInternal medicinebioimpedancemedicineElectric ImpedanceLeukocytesestrogenHumanstietokonetomografiapost-menopausalMuscle SkeletalExerciseGenetics (clinical)Hand Strengthbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologySkeletal muscleta3141computed tomographyTwins MonozygoticMiddle AgedTelomeremedicine.diseasetelomeresObesitypercentage of fatfat-free mass030104 developmental biologyEndocrinologymedicine.anatomical_structuretwin designEstrogenTransgender hormone therapyPediatrics Perinatology and Child HealthBody CompositionFemaletelomeeritbusinessTwin Research and Human Genetics
researchProduct

Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patien…

2021

The aims of this study were to determine the frequency of dialysis and kidney transplantation and to estimate the regularity of comprehensive conservative management (CCM) for patients with kidney failure in Europe. This study uses data from the ERA-EDTA Registry. Additionally, our study included supplemental data from Armenia, Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova, Montenegro, Slovenia and additional data from Israel, Italy, Slovakia using other information sources. Through an online survey, responding nephrologists estimated the frequency of CCM (i.e. planned holistic care instead of kidney replacement therapy) in 33 countries. In 2016, the overall incidence of rep…

0301 basic medicinemedicine.medical_treatment[SDV]Life Sciences [q-bio]030232 urology & nephrologyConservative TreatmentDISEASE0302 clinical medicineGermanyMedicine and Health SciencesRegistriesRenal InsufficiencyKidney transplantationeducation.field_of_studyhemodialysisGreeceRENAL REPLACEMENT THERAPY3. Good healthEuropeperitoneal dialysisItalyNephrologyHemodialysismedicine.medical_specialtyPopulationhemodialysis [Keywords]Peritoneal dialysis03 medical and health sciencesRenal DialysisInternal medicinemedicineHumansRenal replacement therapyeducationDialysisEdetic AcidPortugalbusiness.industryHome hemodialysisCAREmedicine.disease3126 Surgery anesthesiology intensive care radiologyKidney TransplantationTransplantation030104 developmental biologySpainKidney Failure ChronicDONATIONbusinessIrelandtransplantationKidney international
researchProduct

Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis

2019

CTSD (cathepsin D) is one of the major lysosomal proteases indispensable for the maintenance of cellular proteostasis by turning over substrates of endocytosis, phagocytosis and autophagy. Consequently, CTSD deficiency leads to a strong impairment of the lysosomal-autophagy machinery. In mice and humans CTSD dysfunction underlies the congenital variant (CLN10) of neuronal ceroid lipofuscinosis (NCL). NCLs are distinct lysosomal storage disorders (LSDs) sharing various hallmarks, namely accumulation of protein aggregates and ceroid lipofuscin leading to neurodegeneration and blindness. The most established and clinically approved approach to treat LSDs is enzyme replacement therapy (ERT) aim…

0301 basic medicineproteolysisCathepsin DCathepsin DCathepsin BstorageCathepsin L03 medical and health sciencesSequestosome 1Neuronal Ceroid-LipofuscinosesAutophagymedicineAnimalsHumansEnzyme Replacement TherapyeducationMolecular BiologyMice Knockouttherapyeducation.field_of_studyTripeptidyl-Peptidase 1030102 biochemistry & molecular biologybiologyAutophagy; cathepsin D; enzyme replacement therapy; lysosome; neuronal ceroid lipofuscinosis; proteolysis; storage; therapyBrainCell BiologyFibroblastsTripeptidyl peptidase Imedicine.diseaseLRP1Cell biologyDisease Models Animal030104 developmental biologylysosomebiology.proteinAllograft inflammatory factor 1Neuronal ceroid lipofuscinosisneuronal ceroid lipofuscinosisLysosomesResearch PaperAutophagy
researchProduct

Menopause and adipose tissue: miR-19a-3p is sensitive to hormonal replacement

2018

Tissue-specific effects of 17 beta-estradiol are delivered via both estrogen receptors and microRNAs (miRs). Menopause is known to affect the whole-body fat distribution in women. This investigation aimed at identifying menopause-and hormone replacement therapy (HRT)-associated miR profiles and miR targets in subcutaneous abdominal adipose tissue and serum from the same women. A discovery phase using array technology was performed in 13 women, including monozygotic twin pairs discordant for HRT and premenopausal young controls. Seven miRs, expressed in both adipose tissue and serum, were selected for validation phase in 34 women from a different cohort. An age/menopause-related increase of …

0301 basic medicinevaihdevuodetmedicine.medical_treatmentmenopauseAdipose tissueEstrogen receptorMonozygotic twinTHERAPYchemistry.chemical_compoundestrogen therapyAdipocyteTUMOR-SUPPRESSORADIPOCYTE DIFFERENTIATIONmicroRNAestrogeenihoitota3141miR-19a-3pHormone replacement therapy (menopause)ta31423142 Public health care science environmental and occupational healthmicroRNAsadipose tissueMenopauseOncologyhormonihoitoSKELETAL-MUSCLEESTROGEN-RECEPTOR-ALPHASTEM-CELLSResearch PaperEXPRESSIONestrogeenitmedicine.medical_specialtyBODY-COMPOSITION3122 Cancersrasvakudokset03 medical and health sciencesInternal medicinemedicineBREAST-CANCERbusiness.industryagingmedicine.diseasehormonitMONOZYGOTIC TWIN PAIRSikääntyminen030104 developmental biologyEndocrinologychemistrybusinessEstrogen receptor alphaHormoneOncotarget
researchProduct

EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): study protocol for a multicentre, observational trial

2021

Sağır, Özlem (Balikesir Author)

1682Epidemiologyurologic and male genital diseasesacute renal failureAdult Intensive & Critical CareAnaesthesiaCohort Studiessurgerychronic renal failureHumansMulticenter Studies as Topic1506Prospective Studiesadult intensive & critical careurogenital systemIncidenceGeneral MedicineAcute Kidney Injuryfemale genital diseases and pregnancy complicationscritical careRenal Replacement TherapyObservational Studies as Topicacute renal failure; adult intensive & critical care; chronic renal failure; epidemiology; surgeryAcute Renal FailureSurgeryepidemiologyadult intensive &ampChronic Renal Failure
researchProduct

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care

2018

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life;…

2747 Transplantation030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseINTRACRANIAL ANEURYSMS610 Medicine & healthBLOOD-PRESSUREDiseaseClinical practiceGUIDELINES10052 Institute of Physiology03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineQuality of life (healthcare)NursingQUALITY-OF-LIFEPolycystic kidney diseaseMultidisciplinary approachHealth caremedicinePolycystic kidney diseaseCKDMultispecialist care030212 general & internal medicineDisease management (health)ADPKDOUTCOMESTransplantation2727 NephrologyScience & Technologypolycystic kidney diseasebusiness.industryRENAL REPLACEMENT THERAPYPATIENT PERSPECTIVESUrology & Nephrologymedicine.diseasePREVALENCEclinical practiceTransplantationRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]CLINICAL-PRACTICENephrologymultispecialist care570 Life sciences; biologybusinessLife Sciences & Biomedicine
researchProduct